Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication. 

Serum CRP, endothelin levels high in hypertensive patients

06 Aug 2018

In patients with uncontrolled blood pressure and severe hypertension, microvascular dysfunction is more pronounced and serum C-reactive protein (CRP) and endothelin levels are elevated, a recent study has found.

Using nailfold videocapillaroscopy, researchers evaluated microcirculatory parameters in 25 patients with resistant hypertension (RH; mean age 55.5±10.2 years), 25 patients with mild-to-moderate hypertension (MMH; mean age 55.0±9.8 years) and 25 normotensive controls (mean age 39.4±15.8 years).

Median serum CRP levels were significantly elevated in RH and MMH patients relative to the controls (0.36 and 0.21 vs 0.06 ng/dL; p=0.005), but no significant difference was observed between the two hypertensive groups. Levels of other inflammatory biomarkers such as adiponectin and endothelin were comparable among the three groups.

Upon subgroup analyses, individuals who were not on statin medication showed increased median endothelin levels, which reached statistical significance in the MMH and RH groups compared with the controls (26.7 and 24.3 vs 15.09 pg/dL; p=0.0001 and p=0.003, respectively).

Moreover, median serum CRP was significantly higher in the RH group than in the MMH and control groups (0.45 vs 0.17 and 0.06 ng/dL; p=0.04), while red blood cell velocity was significantly lower than in normotensive controls (0.91 vs 0.95; p=0.01).

Restricting the analysis to hypertensive participants, researchers showed that nonuse vs use of statins led to significantly higher median serum endothelin levels in both the RH (24.3 vs 16.5 pg/dL) and MMH (26.7 vs 13.1 pg/dL; p<0.01) groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication.